A pivotal study evaluating tofacitinib (Xeljanz) as induction and maintenance therapy for ulcerative colitis was published on 2017-01-01. This publication, titled 'Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis,' details the efficacy and safety profile of the drug in patients with moderately to severely active disease.
Background
Tofacitinib is a drug investigated for its role in treating various inflammatory conditions. This pivotal study focused on its use in ulcerative colitis, a chronic inflammatory bowel disease. The study specifically addressed patients with moderately to severely active forms of the condition.
Trial design
The 'OCTAVE' study, referenced in the publication, was designed to evaluate both the efficacy and safety profile of tofacitinib (CP-690,550) in patients with moderately to severely active ulcerative colitis. The research aimed to assess the drug's effectiveness as both an induction and maintenance therapy for this patient population.
What this means
The publication of this pivotal study provides important data regarding the use of tofacitinib for ulcerative colitis. As a pivotal study, its findings contribute significantly to the understanding of tofacitinib's potential role in managing moderately to severely active ulcerative colitis, informing clinicians and researchers about its efficacy and safety profile in this challenging disease.
Source
The information regarding this pivotal publication was sourced from PubMed, a database of biomedical literature. The article, titled 'Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis,' was published on 2017-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.